Knowde Group has formed a strategic alliance with LMC Manna Research to boost the quality and performance of clinical trials in cannabis and psychedelic research.
Based in Canada, Knowde Group is a contract research organisation that focuses on cannabis and psychedelic research while LMC Manna Research is a clinical research sites network that offers services for Phase I-IV trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Objective and scientifically comprehensive trials are required for medicinal cannabis and psychedelics, the companies noted.
Psychedelic medicine could offer breakthrough drugs for various psychiatric conditions, including depression and post-traumatic stress disorder.
The World Health Organization statistics show that approximately 450 million people are presently suffering from mental illness globally.
In Canada alone, more than 6.7 million people are affected by mental health problems and one in two face a mental illness by 40 years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataKnowde Group COO Sabrina Ramkellawan said: “We are in a mental health crisis and it’s critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including Phase III large-scale clinical trials.”
The latest alliance will leverage Knowde Group’s expertise and LMC Manna’s Phase I-IV trial capabilities at several research sites across Canada to facilitate and expedite clinical studies of cannabis and psychedelics.
It supports Knowde Group’s aim to set up a global research organisation in the plant-based and progressive medicine field.
The partners will provide strategic recommendations to help companies undertake the correct clinical research programme, regulatory pathway and partners.
They will also offer strategic enrolment of a diverse population, having a database of more than one million patients in Canada and 15 million worldwide.
The alliance will also advance research via early phase expertise, right safety oversight and early phase clinic.
Therapeutic areas covered are psychiatry, pain management, dermatology, neurology, community-based oncology research and smoking cessation.
LMC Manna Research president Karri Venn said: “Collectively, between the two organisations we offer a full-service package from protocol development to timely and successful clinical trial execution.”
In July 2020, LMC Manna Research partnered with IQVIA to enable the launch of the latter’s first Prime Site for clinical investigation in Canada.
